Acute myeloid leukemia echocardiograph and ultrasound

Jump to navigation Jump to search

Acute myeloid leukemia Microchapters


Patient Information


Historical Perspective




Differentiating Acute myeloid leukemia from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings


Chest X Ray

Echocardiograph and Ultrasound



Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute myeloid leukemia echocardiograph and ultrasound On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Acute myeloid leukemia echocardiograph and ultrasound

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute myeloid leukemia echocardiograph and ultrasound

CDC on Acute myeloid leukemia echocardiograph and ultrasound

Acute myeloid leukemia echocardiograph and ultrasound in the news

Blogs on Acute myeloid leukemia echocardiograph and ultrasound

Directions to Hospitals Treating Acute myeloid leukemia

Risk calculators and risk factors for Acute myeloid leukemia echocardiograph and ultrasound

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]


Additional imaging studies that can be useful in acute promyelocytic leukemia include echocardiogram and ultrasound. Echocardiogram is useful for assessing cardiac function in patients receiving anthracycline chemotherapy. Ultrasound is useful for assessing for deep vein thrombosis which is a common complication of acute myeloid leukemia.

Echocardiograph and ultrasound

  • Echocardiograph: An echocardiogram is an essential imaging modality in patients with acute myeloid leukemia receiving anthracycline chemotherapy.[1] Patients who will be receiving anthracycline-based therapy require a baseline echocardiogram to assess the ejection fraction prior to therapy. Anthracyclines are known to cause cardiac toxicity (specifically cardiomyopathy with cumulative anthracycline doses above 500mg/m2). An echocardiogram should be obtained every three months while on therapy with anthracycline. Echocardiogram also applies particularly to cases of high-risk acute promyelocytic leukemia, in which case the standard of care is to give anthracycline along with all-trans retinoic acid.
  • Ultrasound: This is useful for diagnosis of lower extremity thrombosis, which commonly occurs in patients with acute myeloid leukemia.[2]


  1. Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA; et al. (2012). "Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines". Am J Cardiol. 110 (11): 1679–86. doi:10.1016/j.amjcard.2012.07.040. PMC 3496816. PMID 22917553.
  2. Zitek T, Baydoun J, Yepez S, Forred W, Slattery DE (2016). "Mistakes and Pitfalls Associated with Two-Point Compression Ultrasound for Deep Vein Thrombosis". West J Emerg Med. 17 (2): 201–8. doi:10.5811/westjem.2016.1.29335. PMC 4786247. PMID 26973753.


Template:WikiDoc Sources